CD8A and neoplasm: To elicit efficient anticancer immune responses, CD8+ T cells need to go through a series of events in the ‘cancer immune cycle’, including neoantigen production by tumor cells, antigen recognition and antigen presentation by dendritic cells (DCs), and activation of cytotoxic lymphocytes (cytotoxic T lymphocytes, CTLs).